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Abstract 
 
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG 
antibodies rarely bind bivalently using both antigen-binding arms (Fabs) to crosslink between 
spikes, instead resorting to weaker monovalent binding that is more sensitive to Env mutations. 
Synthetic antibodies capable of bivalently binding within single Env trimers (intra-spike 
crosslinking) were previously shown to exhibit increased neutralization potencies. In initial work, 
diFabs joined by varying lengths of rigid double-stranded DNA (dsDNA) were considered. Here 
we investigated whether linkers with different rigidities could enhance diFab potency by 
synthesizing DNA-Fabs containing different combinations of rigid dsDNA and flexible single-
stranded DNA (ssDNA) and created a model that predicts their neutralization potencies. Model 
predictions, verified by experimental data, show that although a long flexible polymer may be 
capable of bivalent binding, it exhibits weak neutralization due to the large loss in entropic 
degrees of freedom during bivalent binding. In contrast, the strongest neutralization potencies 
require a rigid linker that optimally spans the distance between two Fab binding sites on an Env 
trimer. These results inform the design of bivalent anti-HIV-1 therapeutics that utilize avidity 
effects to remain potent against HIV-1 in the face of the rapid mutation of Env spikes. 
 
Significance 
 
Effective antibody-mediated immune responses against pathogens involve tight binding to 
invading particles. IgG antibodies usually accomplish this by simultaneously binding two 
antigen-binding arms (Fabs) to a dense array of antigens on the pathogen – if one Fab 
dissociates, IgGs can remain attached through the second arm, enhancing the likelihood that 
the first Fab will reassociate. This avidity effect enables bivalent IgGs to achieve a higher 
apparent affinity for the pathogen than a monovalent Fab. HIV-1 foils this strategy by having few, 
highly-separated Envelope spikes (Envs) on its surface for IgGs to bind. This forces most anti-
HIV-1 antibodies to bind monovalently, causing IgGs to rapidly dissociate from mutated strains 
of HIV-1 that arise during infection. In this work, we explore the efficacies of an array of 
synthetic antibodies that achieve avidity through bivalent binding to single trimeric Envs. We 
develop a model that uses the geometry of each synthetic antibody to predict its neutralization 
potency, quantifying how entropic effects determine neutralization potencies and presenting a 
way to theoretically design an optimal antibody-based reagent that can bind bivalently to HIV-1 
Env in order to target the virus in the face of its rapid mutation. 
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Introduction 
 
Despite decades of research since its discovery, Human Immunodeficiency Virus-1 (HIV-1) 
continues to threaten global public health (1). While there have been advances in our 
understanding of the mechanisms of infection and the development of preventative and 
therapeutic strategies, there remains no cure for HIV-1 infection. Antiretroviral therapy with 
small molecule drugs can control the progression of the virus, allowing those infected with HIV-1 
to live longer and healthier lives, but the treatment includes detrimental side effects, and when 
discontinued or not taken as prescribed, leads to viral rebound to pre-treatment levels (2). A 
major factor confounding the development of a prophylactic vaccine is the rapid mutation of 
HIV-1, leading to the emergence of many new strains, even within a single individual (3). Thus 
most antibodies raised by the host immune system are strain-specific or neutralize only a subset 
of strains, leading to viral escape from host antibodies.  
 
Recent interest has focused upon the isolation of broadly neutralizing IgG antibodies (bNAbs) 
from a subset of HIV-1–infected individuals (4). These antibodies bind to and block the functions 
of the HIV-1 envelope (Env) spike, the viral protein responsible for fusion of the HIV-1 and target 
cell membranes that leads to entry of the virion’s genetic material into the host cell (5). The 
discovery and characterization of HIV-1 bNAbs has brought new impetus to the idea of 
passively delivering antibodies to protect against or treat HIV-1 infection. bNAbs can prevent 
and treat infection in animal models (6-12) and exhibited efficacy against HIV-1 in human trials 
(13-16). However, HIV-1 Env mutates to become resistant to any single bNAb, as evidenced by 
the fact that NAbs developed in an infected individual, even NAbs that can neutralize large 
numbers of viral variants in laboratory assays, normally fail to neutralize autologous circulating 
viral strains (17-20). As a result, antibodies that develop during HIV-1 infection appear to be 
unable to control the virus in an infected individual. 
 
We previously proposed that one mechanism by which HIV-1 evades antibodies more 
successfully than other viruses arises from the low surface density of Env spikes that can be 
targeted by neutralizing antibodies (21, 22). Compared to viruses such as influenza A, dengue, 
and hepatitis B, the density of Env spikes on the surface of HIV-1 is about two orders of 
magnitude smaller (22). For example, influenza A has ≈450 spikes per virion, whereas each 
HIV-1 virion incorporates only 7-30 Env spikes (average of 14) (22-26), even though both are 
enveloped viruses with ≈120 nm diameters (Fig. 1A). The HIV-1 spikes are the machinery by 
which the virus binds its host receptor CD4 and coreceptor CCR5/CXCR4 to mediate the fusion 
of the host and viral membranes that allows its genome to enter target cells (5). As a 
consequence of its small number of spikes, HIV-1 infection of target cells is inefficient; the 
transmission probabilities for sexually-acquired HIV-1 infection range from 0.4 to 1.4% (27). 
However, the reduced infectivity of HIV-1 comes with a concomitant reduction in the ability of 
antibodies to control the virus, as the surface spikes serve as the only targets for neutralizing 
antibodies that can block infection of target cells (4).  
 
The close spacing of spikes on typical viruses allows IgG antibodies to bind bivalently to 
neighboring spikes (inter-spike crosslinking) using both of their antigen-binding arms (Fabs). 
However, most spikes on HIV-1 virions are too far apart to permit inter-spike crosslinking by 
IgGs, whose antigen-binding sites are separated by ≤15 nm (28). While each homotrimeric HIV-
1 spike includes three binding sites (epitopes) for an antibody, the architecture of HIV-1 Envs 
and distribution of epitopes on the HIV-1 Env trimer prohibits simultaneous binding of two Fabs 
within a single IgG (intra-spike crosslinking) to the same Env (29, 30). We suggested that 
predominantly monovalent binding by anti-HIV-1 antibodies expands the range of Env mutations  
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Fig. 1. Effects of spike density on IgG binding. (A) Close spacing of hundreds of surface spikes on 
influenza A allows bivalent binding of IgGs to adjacent spikes (red boxes), permitting avidity effects in the 
context of low monovalent (i.e., Fab-antigen) affinities. In contrast, HIV-1 has an average of 14 spikes that 
are spaced far apart, and because the HIV-1 spike architecture prohibits simultaneous binding of two 
Fabs to a single Env trimer, most IgGs bind monvalently to HIV-1 Envs (gold boxes). We investigated a 
synthetic homo-diFab designed to bind bivalently to a single HIV-1 spike trimer (blue boxes). (B) 
Schematics of a Fab, an IgG, and a diFab composed of two Fabs joined by a ssDNA and dsDNA linker of 
length d bp flanked on both sides by s=12 bases of ssDNA. (C) Comparison of IC50 values from in vitro 
neutralization assays measuring the potencies of 3BNC60 diFabs with d = 10 to d = 100 bp dsDNA and s 
= 12 bases for neutralizing HIV-1 strain 6535.3 (data from (21)). The IC50 values from (21) for 3BNC60 
Fab and 3BNC60 IgG against HIV-1 strain 6535.3 are shown as blue (Fab) and red (IgG) lines. (D) 
Comparison of hydrodynamic radii of diFabs constructed using linkers containing the indicated numbers 
of dsDNA bps (d) and ssDNA bases (s). Blue bars represent previously-constructed diFabs (Panel C; 
Table 1) (21); purple bars denote new diFabs with longer ssDNA (Table 2). Mean values are plotted with 
error bars for standard deviations of measurements made in triplicate. 
 
 
permitting antibody evasion, whereas reagents capable of bivalent binding through inter- or 
intra-spike crosslinking would be more resistant to Env mutations and thus more potent across 
multiple strains of HIV-1 (21, 22). The hypothesis that HIV’s low spike numbers and low 
densities contributes to the vulnerability of HIV-1 bNAbs to spike mutations is supported by 
independent biochemical and EM studies demonstrating that HIV-1 has an unusually low 
number of spikes that are not clustered (23-26, 31), and that bivalent IgG forms of anti-HIV-1 
NAbs are only modestly more effective than monovalent Fabs, by contrast to bivalent IgGs 
against other viruses, which can be 100s- to 1000s-fold more potent than counterpart 
monovalent Fabs (21, 22, 29, 30). 
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An antibody’s neutralization potency against a virus is related to its antigen-binding affinity, 
which is defined as the binding strength between a Fab and its antigen (32) described by the 
equilibrium dissociation constant KD = [Fab][Ag]/[Fab–Ag], where [Fab], [Ag] and [Fab–Ag] are 
the concentrations of the antibody Fab, antigen, and the complex, respectively (33). In bivalent 
molecules interacting with binding partners that are tethered to a surface, the apparent affinity, 
or avidity, can be enhanced by multivalent binding. Such multivalent interactions are seen in 
many biological contexts including cell-cell communication, virus-host cell interactions, antibody-
antigen interactions, and Fc receptor interactions with antigen-antibody complexes (34). Avidity 
effects benefit these interactions from both kinetic and thermodynamic standpoints: binding 
bivalently to tethered binding partners is advantageous kinetically because if one arm 
dissociates, the likelihood of it finding its binding partner is greater due to the constraint of being 
tethered (35). Avidity effects are also advantageous thermodynamically; whereas binding the 
first arm results in losses of translational and rotational degrees of freedom, the subsequent 
binding of the second arm incurs a smaller entropic cost, thereby increasing the likelihood of the 
bivalent state (35).  
 
In the context of an IgG with two antigen-binding Fabs, the ability to bind bivalently is dependent 
on geometric factors such as the separation distances and orientations of tethered epitopes (36). 
In the case of IgG-virus interactions, the tethered epitopes would be on adjacent spikes during 
inter-spike crosslinking or on individual spikes if intra-spike crosslinking can occur. Although the 
architecture of the HIV-1 spike prevents intra-spike crosslinking (29, 30), we engineered 
reagents (homo- and hetero-diFabs) that can simultaneously bind to a single spike trimer, 
resulting in mean neutralization potency increases >100-fold over a panel of HIV-1 strains (21). 
Our intra-spike crosslinking reagents were IgG Fabs joined by different lengths of double-
stranded DNA (dsDNA), which served as both a rigid linker and a molecular ruler to probe the 
conformations of HIV-1 Env on virions (21) (Fig. 1B). Optimal diFabs inhibited HIV-1 infection of 
reporter target cells more efficiently than the parental IgG or Fab (Fig. 1C; data shown from (21) 
for neutralization of HIV-1 strain 6535.3 by a homo-diFab constructed from 3BNC60, a CD4-
binding site bNAb (37), linked by varying lengths of dsDNA). This response showed a sharp 
dependence on the length of the dsDNA linker between the two Fabs (Fig. 1C), suggesting that 
dsDNA can be used as a ruler to measure the approximate distance between epitope binding 
sites on virion Envs and to design reagents capable of strong intra-spike crosslinking between 
such sites. The large potency increases observed for diFabs with optimal dsDNA linkers 
supports the hypothesis that low spike densities facilitate antibody evasion by HIV-1 (21). 
 
While these results suggested that a rigid, optimal-length linker joining two HIV-1 bNAb Fabs 
could result in synergistic binding and neutralization of HIV-1 through avidity effects, they did not 
rule out the possibility that a flexible linker joining two Fabs could also enhance potency. For 
example, if maximal potency in an intra-spike crosslinking diFab does not require a rigid linker 
spanning the precise distance between epitopes on trimeric HIV-1 Env, it should be possible to 
create IgGs that bind with avidity to any Env epitope using a protein-based flexible linker. A 
more flexible linker could potentially improve the antigen-binding orientation and hence affinity 
of the Fab, but it would also increase the entropic penalty associated with bivalent binding (35). 
To investigate which effect was dominant, flexible Gly4Ser repeats were introduced into the 
hinge regions of IgGs to extend their reach, but the resulting constructs did not show increased 
potencies (38).  
 
In this work, we created 11 new diFabs with DNA linkers to systematically evaluate the effects 
of linker rigidity on synergistic neutralization by a diFab constructed from the CD4-binding site 
bNAb 3BNC60. Starting with (d=62, s=12) (two 3BNC60 Fabs joined by a 62 bp (base pair) 
dsDNA linker flanked by 12 bases of ssDNA on both ends (21)), we considered new linker 
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designs in order to characterize the roles of rigidity and flexibility versus overall length of DNA 
linker within a series of 3BNC60 diFabs. Using in vitro neutralization assays, we found that 
substituting flexible ssDNA for rigid dsDNA in the linker reduced neutralization potency. To 
quantify this effect, we created a statistical mechanics-based mathematical model that 
characterized the various synthetic antibodies we created, demonstrating that the efficacy of 
intra-spike crosslinking/increased neutralization potency could be explained solely by entropic 
effects. Using this model, we can predict the neutralization potential of other synthetic bivalent 
antibodies and of more complicated geometries involving additional Fabs. Insights from our 
synthetic constructs can be adapted to antibody design in other systems in which length and 
rigidity of linkers in multivalent reagents must be balanced to elicit the most effective response. 
 
Results 
 
Experimental results establish parameters for modeling 
Before describing the new diFab designs, we summarize previous results from which we 
derived model parameters used in this work. To evaluate our hypothesis that anti-HIV-1 
reagents that bind bivalently would be more potent across multiple strains of HIV-1 (22), we 
engineered antibody-based molecules to bind bivalently through intra-spike crosslinking (21). 
We first made a library of bNAb Fabs, covalently attached them to ssDNA, and then hybridized 
the ssDNA to different lengths of dsDNA to make diFabs connected by different lengths of 
dsDNA (Fig. 1B). The dsDNA served as a molecular ruler by virtue of its long persistence length 
(dsDNA is essentially rigid up to ≈150 bp) and its 0.34 nm/bp increment (39). We then assayed 
diFabs against a panel of HIV-1 strains to identify optimal distances for increased breadth and 
potency compared to their parental Fabs and IgGs.  
 
We determined the optimal dsDNA linker length for the 3BNC60 diFab by evaluating dsDNA 
linkers using in vitro neutralization assays in which different concentrations of a synthetic 
antibody were evaluated for their ability to prevent HIV-1 infection of target cells (40). We found 
that the 50% inhibitory concentrations (IC50 values) of 3BNC60 diFabs against HIV-1 strain 
6535.3 were sharply dependent on the dsDNA length, with the most potent 3BNC60 diFab 
containing 62 bp of dsDNA with 12 bases of flanking ssDNA on both sides of the linker (Fig. 1C). 
This diFab, here called (d=62, s=12), exhibited synergistic neutralization (up to 167-fold 
increased potency with respect to individual HIV-1 strains and a 19-fold average increase 
across a virus panel), which we hypothesized resulted from avidity effects due to intra-spike 
crosslinking in which the diFab bound to two of its three adjacent epitopes on a single HIV-1 
Env trimer (21). 
 
The length of the double-stranded region of this optimal linker (21 nm) was close to the 
predicted distance (≈20 nm) between the C-termini of adjacent 3BNC60 Fabs (where the DNA 
was covalently attached) bound to a low-resolution open structure of an HIV-1 trimer (41). 
Bridge lengths of ≈60 bp of dsDNA also exhibited the best potencies for 3BNC60 diFabs and 
related CD4-binding site diFabs against other HIV-1 strains, although the neutralization potency 
increases for diFabs containing ≈60 bp of dsDNA were not as pronounced as the 3BNC60 
homo-diFabs assayed against the 6535.3 HIV-1 strain (21). We therefore chose the 
neutralization data for the (d=62, s=12) diFab against the 6535.3 HIV-1 strain for modeling (Fig. 
1C; Table 1). 
 
To model the linkers connecting the two Fabs in our synthetic antibodies, we treated the dsDNA 
as a 1D rigid rod and the ssDNA as a random walk. The former assumption is valid because the 
linkers in all constructs include ≤100 bp of dsDNA, less than its 150 bp persistence length (42). 
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Free ssDNA is flexible with a persistence length between 2-6 bases (43, 44), and because each 
of our constructs consist of ssDNA segments with at least 12 bases, we analyzed the ssDNA as 
a floppy chain using polymer physics models (e.g., the ideal chain model, the worm-like chain 
model) (45).  
 
To experimentally assess the degree to which the flanking ssDNA affects the Fab separation in 
diFabs, we used dynamic light scattering (DLS) (46) to measure the hydrodynamic radii of our 
diFabs. We previously used DLS to show that diFabs with a fixed amount of ssDNA (12 bases) 
and variable numbers of dsDNA bps exhibited increasing radii as dsDNA linker length (21), 
consistent with the assumption that the dsDNA in diFab linkers behaves as a rigid rod. Here we 
used DLS to compare the effects of different numbers of ssDNA bases flanking a dsDNA 
bridging linker (Fig. 1D, where blue bars represent diFabs from Fig 1C (Table 1) and purple bars 
denote new diFabs with longer flanking ssDNA segments (Table 2)). The hydrodynamic radii of 
diFabs did not depend on the length of the ssDNA; e.g., the (d=62, s=12) diFab had the same 
hydrodynamic radius as (d=62, s=42). These results suggest that the ssDNA in the linker does 
not behave as an ideal free polymer, but rather that its extension is more limited within the diFab 
experimental system.  
 
Because the DLS data suggested that the effective length of ssDNA in our system is more 
confined than for free ssDNA, the contribution of the ssDNA was determined empirically by 
comparing the diFab neutralization data to two models for ssDNA: (1) a model in which the 
ssDNA in the diFab linker was completely ignored by assuming it has zero length (Fig. 2A), and 
(2) a model in which the ssDNA contributed to the linker but with a smaller persistence length 
than when free in solution (Fig. 2B).  
 
One further model parameter, 𝑙flex, was included to account for variations in the distance 
between the C-termini of the two 3BNC60 CH1 domains to which the DNA was attached due to 
the following factors: (i) The Fab CH1-CL domains can adopt different conformations with respect 
to VH-VL (47) such that the locations of the CH1 C-terminus could shift by up to ≈1 nm, (ii) 
Residues C-terminal to CH1 residue 217 are disordered in the 3BNC60 Fab structure (37), thus 
the position of the CH1 residue to which the DNA was attached (Cys233) is uncertain within ≈1 
nm, (iii) The ssDNA is covalently linked to the CH1 residue Cys233 using an amine-to-sulfhydryl 
crosslinker (Sulfo-SMCC) (Methods), which exerts unknown effects on the length and the 
degree of flexibility between the ssDNA and Fab.  
 
Relating Antibody Neutralization to the Probability that an HIV-1 Spike is Bound 
We next created a mathematical model of diFab efficacy based on the properties of the linker. 
To lay the groundwork for this model, we first related the ability of a diFab to neutralize an HIV-1 
virion to the probability that an Env spike on the surface of HIV-1 will be bound. Each Env spike 
is a homotrimer with three identical binding sites for a 3BNC60 Fab (48). The spikes are 
assumed to be sufficiently far apart that a diFab cannot crosslink between neighboring spikes. A 
diFab with the right geometry can bind to two binding sites on the same spike, whereas a diFab 
whose linker is either too short or too long can bind to only a single Env epitope ( 
Fig. A). Previous experiments suggested that only one of the three CD4 binding sites on an Env 
spike need to be bound to prevent the Env from functioning in membrane fusion (49). We 
imposed a soft threshold for virus entry where the ability of an HIV-1 virion to infect increases 
linearly from zero (when all spikes are bound by diFabs) to some maximum value (when all 
spikes are unbound) that is constant across all HIV-1 molecules (Appendix A). While some 
studies suggested that two or three Env trimers are required for HIV-1 to infect (50, 51), other 
studies found that only one functional Env trimer was required for target cell fusion (52); thus   
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Fig. 2. Modeling the optimal linker length for a diFab. (A) DLS data suggested that the diFab linker 
can be modeled by either (A) ignoring the ssDNA entirely or (B) including the ssDNA with a smaller 
persistence length. In both models, the Boltzmann weight of the monovalent state is dictated by the 𝐾𝐷
(1)
 
(the dissociation constant between the Env trimer and the first diFab arm), while the weight of the bivalent 
state is dictated by a geometric or avidity factor (𝛼 𝑛 in Panel A and ?̃?  ?̃? in Panel B) shown in a gray box. 
This geometric factor depends upon the length of the dsDNA and ssDNA in each construct as well as on 
the optimal length 𝑙linker of the linker between two bound Fabs and the flexibility 𝑙flex between the CH1-CL 
and VH-VL domains of a bound Fab. The ability to neutralize is given by the sum of the probabilities of the 
monovalent and bivalent states. (C) The relative probability that a diFab with d bp dsDNA and s bases 
ssDNA in its linker is bivalently (𝑝2) versus monovalently (𝑝1) bound. (D) Comparison of experimental 
(points) and predicted (curves) effects of dsDNA bridge lengths on the neutralization potencies of the 
3BNC60 diFabs against HIV-1 strain 6535.3 (data from (21)). Experimental neutralization IC50s showed a 
sharp dependence on dsDNA linker length, with an optimum length at d=62 bp. Parameters for both 
models were inferred by nonlinear fitting (see Methods). 
 
 
our model allowed a virion with a single unbound Env trimer to infect, albeit 1/𝑛 as effectively as 
a virion with 𝑛 unbound trimers.  
 
Given these assumptions, the ability of a diFab to neutralize HIV-1 is proportional to the 
probability that at least one of the CD4 binding sites of an HIV-1 spike will be bound by a 
3BNC60 Fab (Appendix A). For example, if each Env protein has a 75% chance to be bound by 
a diFab, an average of 75% of the spikes on each virion will be bound, and by the linearity 
assumption, the HIV virions will be 75% neutralized. This enables us to relate the 
experimentally-determined % neutralization for diFabs in Tables 1 and 2 to the theoretically-
tractable probability that a single Env spike will be bound either monovalently or divalently by a 
diFab. Avidity effects will allow an optimal diFab to bind more tightly (with a lower apparent KD) 
to a spike, increasing the binding probability and the neutralization potency. 
 
The Avidity of a diFab is Constrained by the Length of Rigid dsDNA and Essentially 
Independent of Flanking Flexible ssDNA 
To calculate the probability that any of the 3BNC60 binding sites on an HIV-1 spike are 
occupied, we enumerated three potential states of the spike, which represent a single diFab 
bound to zero, one, or two adjacent binding sites. Because measurements of the hydrodynamic 
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radii of multiple constructs suggested that the ssDNA components of the linker did not 
measurably alter its size, we first modeled the system as a pair of Fabs joined together with 
dsDNA and ignored the contributions of the ssDNA (Fig. 2A). 
 
When a diFab transitions from the unbound state (with probability 𝑝0) to a monovalently-bound 
state (with probability 𝑝1), it loses translational and rotational entropy but gains favorable binding 
energy (53) leading to the relative probability 
𝑝1
𝑝0
=
[Ab]
𝐾D
(1)
, [1] 
where 𝐾D
(1)
 is the equilibrium dissociation constant of the first diFab arm binding to Env. Note 
that 𝐾D
(1)
 incorporates the geometry of the Env trimer, namely, that there are three 3BNC60 
binding sites on a trimeric HIV-1 spike and that the diFab can bind monovalently with either arm. 
Importantly, the transition from an unbound to a monovalently-bound diFab is independent of 
the composition of the diFab’s linker, since the loss in translational and rotational entropy 
increases slowly with the size of a particle and hence can be assumed to be the same for all 
constructs. This implies that the constant 𝐾D
(1)
 will be the same for all diFabs in this study and 
that it also characterizes the 3BNC60 Fab’s binding to the Env trimer. By assuming that the 
neutralization potency of the Fab is proportional to how well it binds to the HIV-1 spike, the 
value of 𝐾D
(1)
 is given by the Fab IC50 = 74 ± 31 nM (see Methods), a value consistent with 
experimental KD values reported for binding of a Fab from a CD4-binding site bNAb to a soluble, 
trimeric form of HIV-1 Env (54). In viral contexts in which the relationship between the apparent 
KD of an antibody and its IC50 is more complex, the dissociation constant could instead be 
inferred by nonlinear fitting.  
 
We now turn to the transition from a monovalently-bound diFab to a bivalently-bound diFab. The 
ability to bivalently bind strongly depends on the size of the diFab’s linker, since having too large 
or too small a linker will preclude bivalent binding through intra-spike crosslinking. The relative 
probability of each energy state is proportional to its Boltzmann weight, 𝑒−𝛽(𝐸−𝑇𝑆) = Ω 𝑒−𝛽𝐸, 
where 𝛽 =
1
𝑘𝐵𝑇
, 𝐸 is the energy, 𝑇 is the temperature (37˚C), 𝑘𝐵 represents Boltzmann’s 
constant, 𝑆 = 𝑘𝐵 log Ω is the entropy, and Ω is the number of microstates with a given energy. 
Thus, the relative probabilities of the bivalent and monovalent states satisfy  
𝑝2
𝑝1
=
Ω2
Ω1
𝑒−𝛽(𝐸2−𝐸1) [2] 
where 𝑝𝑗, 𝐸𝑗, and Ω𝑗 represent the probability, energy, number of microstates when 𝑗 Fabs are 
bound to an Env. 
 
The number of configurations Ω1 for a monovalently-bound diFab is proportional to the degrees 
of freedom available when one Fab is bound to its epitope and the second Fab is unbound and 
tethered to the first by DNA. Since the associated entropy of this motion increases slowly with 
size, we assume that Ω1 is constant across all diFabs. Similarly, the binding energy 𝐸2 − 𝐸1 
gained when the second Fab in a diFab binds to the HIV-1 spike is the same for all diFabs we 
consider. 
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The number of configurations Ω2 of the bivalent state depend upon the entropy of the dsDNA 
linker joining the C-termini of the two bound Fabs separated by a width 𝑙linker (Fig. 2A). In 
addition, each Fab is inherently flexible at the join between the CH1-CL domains and the VH-VL 
domains, as denoted by 𝑙flex. If we approximate 𝑙linker and 𝑙flex as colinear so that the problem 
becomes one dimensional (see Appendix B), the number of microstates corresponding to the 
bivalently-bound state satisfies 
Ω2 =
max(𝑙flex − |𝑙dsDNA − 𝑙linker|, 0)
Δ𝑙
≡
𝑛(𝑙dsDNA)
Δ𝑙
[3] 
where 𝑛(𝑙dsDNA) equals the length between the outer-most dsDNA orientations capable of 
bivalent binding (Appendix B Fig. S2), and Δ𝑙 is a constant representing the discretization of this 
length so that Ω2 is unitless. In short, 𝑛(𝑙dsDNA) quantifies how the geometry of the diFab affects 
its ability to bivalently bind to a spike. 
Using Eqs. 1-3 and the normalization condition, 𝑝0 + 𝑝1 + 𝑝2 = 1, the probability that at least 
one of the three Fab epitopes on an HIV-1 spike will be bound can be written as 
𝑝1 + 𝑝2 =
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) 𝛼 𝑛(𝑙dsDNA)
1 +
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) 𝛼 𝑛(𝑙dsDNA)
[4] 
where we have separated the constant 𝛼 =
1
Ω1Δ𝑙
𝑒−𝛽(𝐸2−𝐸1), which does not depend on the diFab 
geometry, from 𝑛(𝑙dsDNA), which does. Because 𝑝1 + 𝑝2 is proportional to the % neutralization of 
the HIV virion, the IC50 of each diFab with the contribution of the ssDNA excluded is given by  
IC50
exc ssDNA =
𝐾D
(1)
1 + 𝛼 𝑛(𝑙dsDNA)
. [5] 
Nonlinear fitting the IC50 values of all diFab constructs in Tables 1 and 2 led to the dissociation 
constant 𝐾𝐷
(1)
= 74 nM characterizing the first diFab arm binding to Env, the optimal linker length 
𝑙linker = 21 nm between bound Fabs, the flexibility 𝑙flex = 1.8 nm between the Fab CH1-CL and 
VH-VL domains, and the avidity constant 𝛼 = 70 (see Methods). Fig. 2D (gray line) shows the 
model predictions which roughly approximate the shape of the IC50 values. diFabs that are too 
long or too short cannot bivalently bind, leading to a sharp transition in the IC50 for dsDNA 
shorter than 𝑙linker − 𝑙flex = 19.2 nm (57 bp) or longer than 𝑙linker + 𝑙flex = 22.8 nm (69 bp). We 
hypothesized that including the ssDNA in the model would smooth the transition from the 
bivalent to purely monovalent binding, and next explored how the effects of the ssDNA in the 
linker could be modeled. 
With contributions of ssDNA included, the distance 𝑙linker between the C-termini of bivalently 
bound Fabs must be spanned by the rigid dsDNA segments as well as the two flanking ssDNA 
strands (Fig. 2B). We modeled each ssDNA segment as a random walk using an ideal chain 
model with a persistence length of 𝜉ssDNA = 0.1 nm inferred by nonlinear fitting (see Methods). 
Note that this persistence length is smaller than the length of a ssDNA base (0.63 nm) to 
account for the DLS data showing no effects on measured hydrodynamic radii of diFabs with 
linkers containing different amounts of ssDNA (Fig. 1D).  
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Of the multiple configurations that two ssDNA random walks can take on, only a small fraction 
will end at the proper distance 𝑙linker to allow a diFab to bivalently bind. The probability density 
that the linker will obtain one of these limited configurations can be computed analytically 
(Appendix C) as  
𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) =
1
𝑙linker  𝑙dsDNA
√
3
32 𝜋3𝑙ssDNA𝜉ssDNA
𝑒
−
3(𝑙linker
2 +𝑙dsDNA
2 )
8 𝑙ssDNA𝜉ssDNA sinh (
3 𝑙linker  𝑙dsDNA
4 𝑙ssDNA𝜉ssDNA
) , [6] 
where 𝑙dsDNA = 𝑑 (0.34
nm
bp
) and 𝑙ssDNA = 𝑠 (0.64
nm
base
) represent the length of dsDNA and ssDNA 
segments in the linker, respectively. Analogously to Eq. 3, the flexibility of the Fab implies that 
the dsDNA and ssDNA can span any length from 𝑙linker − 𝑙flex to 𝑙linker + 𝑙flex (see Appendix C). 
In the limit where 1 nm ≈ 𝑙flex ≪ 𝑙linker ≈ 20 nm, the number of bivalent configurations is 
proportional to the simple form 
?̃?(𝑙dsDNA, 𝑙ssDNA) = 𝑙flex
2 𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker). [7] 
 
As in the model neglecting ssDNA described in the previous section, all other constants that are 
independent of the diFab geometry can be absorbed into a prefactor ?̃? in the bivalent state (Fig. 
2B). Thus, the occupancy probability for an HIV-1 spike is given by the same functional form as 
Eq. 4, namely, 
𝑝1 + 𝑝2 =
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) ?̃? ?̃?(𝑙dsDNA, 𝑙ssDNA)
1 +
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) ?̃? ?̃?(𝑙dsDNA, 𝑙ssDNA)
[8] 
with an analogous IC50 given by 
IC50
inc ssDNA =
𝐾D
(1)
1 + ?̃? ?̃?(𝑙dsDNA, 𝑙ssDNA)
. [9] 
 
Nonlinear fitting Eq. 9 to the IC50s in Tables 1 and 2 led to the parameter values 𝐾𝐷
(1)
= 74 nM, 
𝑙linker = 21 nm, 𝑙flex = 1.8 nm, ?̃? = 5.2 × 10
5, and the ssDNA persistence length 𝜉ssDNA = 0.1 
(see Methods and Appendix D). The avidity parameter ?̃? is orders of magnitude larger than the 
corresponding parameter (𝛼 = 70) in the model neglecting ssDNA because the probability that 
the 3D random walk encompassed within ?̃?(𝑙dsDNA, 𝑙ssDNA) will end at the particular distance to 
enable bivalent binding is small, thereby requiring a correspondingly larger avidity parameter. 
 
Fig. 2C plots the probability that a diFab will be bivalently bound (𝑝2) relative to the 
monovalently bound probability (𝑝1) as the amount of dsDNA (d) and ssDNA (s) in the linker 
varies. The model captures the trend that bivalent binding is most likely when 𝑙linker ≈ 𝑙dsDNA 
around d=62 bp dsDNA, with the peak shifting very slightly leftwards as the amount of ssDNA 
increases, demonstrating how the root-mean-squared length of the ssDNA slowly increases. 
The black curve in Fig. 2D shows how the model incorporating ssDNA (Eq. 9) provides a 
broader transition of the bivalent to monovalent binding more in line with the published diFab 
data (21). Hence, we restrict the following analysis to this latter model that includes the 
contributions from both ssDNA and dsDNA within the linker. 
 
The diFab Model Allows Bivalent Binding Only when the dsDNA Length is Approximately 
Equal to the Length of the Linker it Spans 
To gain a qualitative understanding of the model including ssDNA (Eq. 9), we examined it in two 
limits: near the optimal geometry 𝑙dsDNA ≈ 𝑙linker where the ability to bind bivalently is maximum, 
and far from the optimal limit when the diFab is too short or too long to permit bivalent binding 
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through intra-spike crosslinking. Note that all these statements also hold for the model excluding 
ssDNA (Eq. 5) provided ?̃? → 𝛼 and ?̃? → 𝑛. 
 
Near the optimal limit, corresponding to 𝑙dsDNA ≈ 𝑙linker or 𝑑 ≈ 62 bp, HIV-1 neutralization will 
occur predominantly from the bivalently-bound configuration rather than the monovalent state, 
𝑝2
𝑝1
= ?̃? ?̃?(𝑙dsDNA, 𝑙ssDNA) ≫ 1. Hence, the system is well approximated with each spike either 
being unbound or bivalently-bound such that 
IC50 ≈
𝐾D
(1)
?̃? ?̃?(𝑙dsDNA, 𝑙ssDNA)
,    (near optimal geometry) [10] 
corresponding to the trough in the black curve in Fig. 2D. If the potency of diFab 1 is IC50
(1)
, and 
the potency of diFab 2 with a different linker is IC50
(2)
, the latter diFab’s potency will be shifted 
relative to the former by 
IC50
(2)
IC50
(1)
=
?̃? (𝑙dsDNA
(1)
, 𝑙ssDNA
(1)
)
?̃? (𝑙dsDNA
(2)
, 𝑙ssDNA
(2)
)
. [11] 
In other words, the relative potency of both diFabs is determined solely by the separation 
distances between the two Fabs in the diFabs, so that the entropy, rather than the energy, 
determines which diFab will be more effective.  
 
When the linker in a diFab becomes too small (𝑙dsDNA ≲ 𝑙linker − 𝑙flex) or too large (𝑙dsDNA ≳
𝑙linker + 𝑙flex), the diFab loses the ability to bind bivalently (𝑛(𝑙dsDNA) ≈ 0) and the IC50 attains a 
constant value 
IC50 ≈ 𝐾D
(1)
    (far from optimal geometry) [12] 
shown as a pink dashed line in Fig. 2D, which is roughly consistent with neutralization data for 
long and short diFabs.  
 
Altering the Fraction of ssDNA and dsDNA in the Linker 
We next investigated how well the probability of diFab binding (Eq. 9) quantitatively 
characterized the neutralization of new diFab constructs. We first tuned the rigidity of the linker 
while keeping the length of the DNA segment fixed. Starting with the optimal construct (d=62, 
s=12), five new diFabs were created with different amounts of dsDNA d flanked by two ssDNA 
segments s maintaining d+2s=86 bases (Fig. 3A), and their neutralization of HIV-1 strain 6535.3 
was assessed using an in vitro neutralization assay (Fig. 3B; Table 2). We found that increasing 
the fraction of ssDNA from the optimal (d=62, s=12) diFab decreased potency; e.g., changing 
d=62 bp to d=58 bp decreased the potency by 4-fold (IC50 = 2.0 nM for (d=58, s=14) compared 
with 0.5 nM for (d=62, s=12)), while constructs with d ≤ 50 exhibited uniformly poor 
neutralization (IC50 values >30 nM), suggesting that each of the latter constructs could only bind 
monovalently. Similar trends were observed for the potencies of the new diFabs against a 
different HIV-1 strain, THRO4156 (Appendix E Fig. S7), suggesting that ssDNA bases cannot 
compensate for the optimal 62 bp length of dsDNA in the linker of a 3BNC60 diFab. 
 
The drop in diFab efficacy when ssDNA is traded for dsDNA is surprising considering that free 
ssDNA has a persistence length of 2-6 bases (43, 44), so that constructs such as (d=62, s=12) 
and (d=58, s=14) might be predicted to behave nearly identically, with the extra flanking ssDNA 
compensating for the shorter dsDNA. Indeed, when the flanking ssDNA is modeled with a  
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Fig. 3. Effects of linker rigidity on diFab potency. (A) Schematics of 3BNC60 diFabs with different 
proportions of dsDNA and ssDNA in their linkers. The linkers were constructed to span 86 bases of DNA, 
of which d = 62, 58, 50, 40, 30, or 20 bases were dsDNA. (B) Experimental results from in vitro 
neutralization assays comparing potencies of diFabs shown in panel A against HIV-1 strain 6535.3 (data 
points represent the average of duplicate measurements). (C) For clarity, we compare the model results 
(solid lines) to the experimental best-fit curves (dashed lines). See Table 2 for IC50 values derived from 
the theoretical and experimental curves. 
 
 
persistence length of 2 bases, the d=62 bp, d=58 bp, and d=50 bp constructs exhibit similar 
potencies (Appendix D Figure S5B) in contrast to the experimental results in which the d=58 bp 
and d=50 bp diFabs were less potent. Taken together with the DLS measurements (Fig. 1D), 
these results provide further justification for the idea that the ssDNA diFabs exhibit a shorter 
persistence length than free ssDNA. Indeed, the IC50 values for the rigidity diFabs (Fig. 3A; 
Table 2) were nearly identical to the corresponding constructs with the same number of dsDNA 
bps but different lengths of ssDNA (Fig. 1B and Table 1), demonstrating that the amount of 
ssDNA negligibly influenced the neutralization potency of the diFab. Using the same parameters 
as in Fig. 2D, we found the best agreement between the experimental neutralization curves 
(dashed) and the model (solid lines) using a persistence length of 0.1 nm (Fig. 3C). Using the 
model to extrapolate to other diFabs in this family with d bp dsDNA and s=(86-d)/2 bases 
ssDNA led to nearly identical results to those shown in Fig. 2D (black line) for constructs with 
the same d but s=12; the IC50 quickly increased as dsDNA was traded for ssDNA and saturated 
at d≈50 to the value 𝐾𝐷
(1)
= 74 nM. 
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Fig. 4. Effects of extra long ssDNA in linkers on diFab potency. (A) Schematics of 3BNC60 diFabs. 
(B) Experimental in vitro neutralization assays against HIV-1 strain 6535.3 (data points represent the 
mean of duplicate measurements). (C) Comparison of experimental results (dashed lines) with the model 
(solid lines). See Table 2 for IC50 values derived from the theoretical and experimental curves. 
 
 
Extra Long ssDNA Segments are Characterized by a Short Persistence Length 
Because the length of ssDNA in the previous constructs minimally affected diFab potency, we 
constructed diFabs with extra long ssDNA regions to test whether the ssDNA in this limit has an 
appreciable effect (Fig. 4A; Table 2). If the size of the ssDNA grows slowly with its length, we 
would expect that constructs with increased ssDNA, such as (d=62, s=17) and (d=62, s=42), 
would neutralize less potently than their counterpart (d=62, s=12) with the same length of 
dsDNA. We found linkers with a relatively short ssDNA flanking region had similar potencies, 
IC50 = 0.5 nM (d=62, s=12) and IC50 = 0.6 nM (d=62, s=17), which slightly decreased when a 
larger amount of ssDNA was added to the optimal d=62 bp linker, IC50 = 1.8 nM (d=62, s=42) 
(Table 2). 
 
On the other hand, since the size of ssDNA grows slowly with the number of bases, we would 
expect that the efficacy of a sub-optimal diFab such as (d=50, s=12) (Fig. 1C) would improve 
with longer flanking ssDNA that might be better able to compensate for the short dsDNA. 
Although variability in the data made it difficult to see such trends – the neutralization IC50 
counterintuitively increased from 8.5 nM (d=50, s=12) to 31 nM (d=50, s=22) before decreasing 
as expected to 6.1 nM (d=50, s=62) – the model predicts that the IC50 values should continually 
decrease as ssDNA is added, although this effect is minimal. More precisely, the predicted IC50 
= 69 nM for (d=50, s=12) should monotonically decrease until it hits the minimum value IC50 = 3 
nM for (d=50, s=200), past which point the IC50 will slowly increase as the ssDNA makes the 
diFab too long to optimally bind bivalently. Taken together, these results emphasize that while  
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Fig. 5. Effects of gaps in dsDNA portions of diFab linkers on potency. (A) Schematics of 3BNC60 
diFabs with ssDNA gaps interspersed within the dsDNA portion of the linker. (B) Experimental in vitro 
neutralization assays against HIV-1 strain 6535.3 show that these diFabs neutralize weakly (data points 
represent the average of duplicate measurements). (C) Comparison of experimental results (dashed 
lines) with the model presented in Appendix F (solid lines). See Table 2 for IC50 values derived from the 
theoretical and experimental curves. 
 
 
the ssDNA may play a minor role in determining a diFab’s efficacy, the length of the rigid dsDNA 
is the single most important factor that determines diFab potency. 
 
Adding ssDNA Gaps makes dsDNA Flexible and Decreases diFab Efficacy 
As a final probe of the effects of linker flexibility, we investigated the potency of two diFabs in 
which the dsDNA linker was interspersed with short ssDNA segments (Fig. 5A; Table 2). These 
constructs, denoted by (5105105105) and (5105225105), contained the same lengths of DNA as 
(d=50, s=12) and (d=62, s=12) in Table 1. However, the dsDNA in (5105105105) and (5105225105) 
was flanked by an extra 5 bases of ssDNA on both sides and interrupted in two places by 5 
bases of ssDNA. Both new constructs neutralized HIV-1 strain 6535.3 only weakly with IC50 
values >30 nM, by contrast to their counterparts, which had IC50 values of 8.5 nM for (d=50, 
s=12) and <1 nM for the optimal (d=62, s=12) construct (Tables 1 and 2). These results again 
emphasize that optimal neutralization potency for a 3BNC60 diFab requires a rigid linker that 
spans a distance dictated by 62 bp and show that interrupting a diFab with a sub-optimal 50 bp 
dsDNA linker with flexible ssDNA further decreases its potency.  
 
Our model can be generalized to analyze these constructs by considering the inner ssDNA 
segments as simple hinges with no length so that the dsDNA can now be characterized as a 
random walk composed of three steps (Appendix F). The two outer ssDNA segments can be 
modeled as a random walk with a persistence length of 0.1 nm. For the larger of the two 
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constructs, (5105225105), the 42 bp of dsDNA would account for a maximum of only 14 nm when 
arranged linearly, thus the two outer ssDNA segments would have to stretch outwards by at 
least 7 nm (11 bases) to achieve the optimal separation distance of 21 nm in the unlikely event 
that all of the DNA segments were colinear. The shorter construct in Fig. 5A (5105105105) would 
require the ssDNA to stretch even further to achieve maximal potency. Hence, the two gapped 
diFabs should only bind monovalently with an IC50 given by Eq. 12, as confirmed by the data 
and model in Fig. 5B,C and Table 2. Note that even if the dsDNA region of the linker were made 
longer, increasing the dsDNA flexibility in this manner increases the entropy lost when going 
from the monovalently- to bivalently-bound states and hence decreases the neutralization 
potency of the diFab. In Appendix F, we use the model to quantify the decrease in potency as 
the dsDNA in the optimal (d=62, s=12) construct is broken into multiple segments. 
 
Discussion 
 
The low density of Env spikes on HIV-1 potentially enables the virus to mitigate the host 
antibody response by hindering host IgGs from using both antigen-binding Fabs to bind 
bivalently, thereby expanding the range of HIV-1 mutations permitting antibody evasion (21, 22). 
The observation that a mutant simian immunodeficiency virus (SIV) with a higher number of Env 
spikes reverted to its normal spike number of ≈14 when propagated in non-human primate hosts 
is consistent with selection against those viruses that facilitate the ability of host IgGs to bind 
bivalently through inter-spike crosslinking (55). Although HIV-1 may be more infectious and 
hence spread more rapidly with more Env trimers (56), the immune system apparently applies 
selective pressure that keeps the Env spike count per virion low, presumably to prevent anti-
HIV-1 IgGs from utilizing avidity effects to counter the lower intrinsic Fab-Env affinities that 
result from rapid mutation of Env. Antibody isotypes such as dimeric IgA or pentameric IgM 
have increased valencies (four and ten Fabs, respectively) compared to the two Fabs of an IgG, 
thus allowing for increased avidity effects during antibody binding to a pathogen. However, most 
of the neutralizing activity in the sera of HIV-1–positive individuals is attributed to IgGs (57, 58), 
and converting an anti-HIV-1 IgG broadly neutralizing antibody to an IgA or IgM has minimal 
effects on potency in standard neutralization assays (59, 60). Thus, most antibodies against 
HIV-1 Env must resort to monovalent binding by IgGs in the absence of avidity effects that 
would strengthen their interactions with other pathogens. 
 
Bivalent binding to single Env trimers is another way to utilize avidity effects to counteract the 
low spike density of HIV-1. Although the architecture of HIV-1 Env trimers prohibits 
simultaneous binding of both Fabs of conventional, host-derived IgGs (29, 30), we constructed 
synthetic antibodies (Fig. 1B) (diFabs constructed from Fabs from a neutralizing anti-HIV-1 IgG 
joined by a linker containing rigid dsDNA flanked by flexible ssDNA) designed to achieve intra-
spike crosslinking; i.e., bivalent binding to adjacent Fab binding sites on a single Env trimer. In 
previous work, we measured the neutralization potencies of an array of diFabs with different 
dsDNA lengths and found that the linker in the optimal 3BNC60 diFab had 62 bp (21 nm) 
dsDNA. 
 
The optimal 21 nm length of the dsDNA portion of the linker can be compared to the distance 
between adjacent 3BNC60 Fabs in various conformations of HIV-1 Envs. It has been shown 
that HIV-1 Env trimers adopt multiple conformations on virions (24, 61) and in the soluble 
native-like forms used for structural studies (48). For example, binding of the host CD4 receptor 
induces outward displacements of the three Env gp120 subunits, resulting in an open 
conformation in which the coreceptor binding sites on the trimer apex V3 loops are exposed (62-
65) and which rearranges further upon coreceptor binding and subsequent membrane fusion. 
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We measured the distances between adjacent 3BNC60 epitopes on Env trimers in different 
conformations using a new cryo-EM structure of 3BNC117 Fab (a close relative of 3BNC60 
(37)) bound to a closed Env trimer (66). Measurements from this single-particle cryo-EM 
structure allows estimation of the average position of the C-terminal CH1 domain residue to 
which the DNA in our diFabs was covalently attached, since Fabs in cryo-EM structures are not 
influenced by crystal packing forces that can alter the CH1-CL domain position relative to the VH-
VL domains in X-ray structures (47). We used the 3BNC117 Fab-gp120 portion of the cryo-EM 
structure to measure the distance between adjacent Fab CH1 C-termini in the closed 
conformation of Env and then modeled a 3BNC60-gp120 protomer into three recent cryo-EM 
structures of Env trimers in different conformations: an open Env bound by the b12 bNAb in 
which the coreceptor binding sites on the V3 loops are not exposed (63), an open CD4-bound 
Env structure with exposed V3 loops (63), and a partially-open CD4-bound Env in which the 
gp120 subunits adopted positions mid-way between closed and fully open (64). From these 
structures, we measured distances of 15.8, 20.3, 20.4, and 20.1 nm between C-termini of 
3BNC60 Fab CH1 domains modeled onto the closed, b12-bound open, CD4-bound open, and 
CD4-bound partially-open Env conformations, respectively (see Methods). Although monovalent 
CD4-binding site bNAb Fabs bind the closed Env trimer conformation (48), the 21 nm length of 
the dsDNA in the optimal (d=62, s=12) diFab more closely matched measured distances for the 
open Env trimer structures, perhaps indicating that the diFab captured an open Env 
conformation that could be neutralized potently by a reagent binding through intra-spike 
crosslinking. 
 
To further probe the result that an optimal linker has 62 bp dsDNA, we created an array of 
diFabs with variable amounts of rigid dsDNA and flexible ssDNA (Tables 1 and 2), enabling us 
to tune both the length and rigidity of the DNA linker. In order to provide a conceptual framework 
to understand how these synthetic antibodies function, we developed a statistical mechanics-
based model to predict diFab potencies for inhibiting infection of the 6535.3 strain of HIV-1. By 
assuming that (i) each homotrimeric spike is unable to help infect a host cell when any one of its 
three epitopes are bound by Fab, and (ii) that the infectivity of a virion varies linearly with the 
number of unbound Env, we showed that the neutralization of a virion is proportional to the 
probability that any single Env protein is bound by a Fab (Appendix A). DLS measurements 
confirmed that the hydrodynamic radii of the diFabs was determined by the length of their rigid 
dsDNA and essentially independent of the length of ssDNA (Fig. 1D). Consequently, these 
constructs were best characterized by modeling the ssDNA with a smaller persistence length to 
account for the DLS data (Fig. 2D). This framework enabled us to translate the linker-dependent 
entropy and energy of binding to an HIV-1 Env trimer into a predicted neutralization potency for 
each diFab.  
 
The first set of diFabs we created explored the effects of linker rigidity. These constructs had the 
same total length of DNA (86 bases) but differed in their fractions of dsDNA and ssDNA (Fig. 3). 
We found that as the dsDNA decreased from the optimal d=62 to d=58, 50, 40, 30, and 20 bp, 
the potency of the antibodies rapidly decreased so that the four constructs with d≤50 neutralized 
only as effectively as the monovalent Fab. From a modeling perspective, the short ssDNA 
persistence length implies that the ssDNA plays a minor role in determining diFab potency. 
Hence, the constructs composed of d bp dsDNA and s=(86-d)/2 bases ssDNA should behave 
similarly to the constructs with d bp dsDNA and s=12 bases ssDNA in Fig. 1C and Table 1, as 
verified experimentally by comparing IC50s of constructs with the same dsDNA lengths (Tables 1 
and 2). In other words, decreasing the dsDNA length shortened the length of the diFabs to the 
point where only monovalent binding was possible when d≤50. 
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A second set of diFabs explored whether extra long ssDNA segments can alter diFab potency 
(Fig. 4). The observed effects were minor; for example, the observed IC50 = 0.5 nM of the 
optimal construct (d=62, s=12) slightly decreased when 30 bases of ssDNA were added to both 
flanking ssDNA segments, resulting in an IC50 = 1.8 nM for (d=62, s=42) (Table 2). These 
results reaffirm that the length of dsDNA in the linker has greater impact on diFab potency than 
the length of ssDNA. 
 
Finally, we considered two additional diFabs that introduced ssDNA gaps within the dsDNA 
portion of the linker (Fig. 5). Both constructs exhibited poor neutralization potencies comparable 
to that of a monovalent Fab. Our model affirmed that introducing flexibility into the dsDNA in this 
manner increases the entropic cost of bivalently binding (see Appendix F). 
 
Although our model successfully reproduced the neutralization curves of the new synthetic 
diFabs evaluated here, we point out several factors of the HIV-1 system that the model neglects. 
First, the model does not consider potential diFab binding between adjacent Env trimers, 
although this binding should be minimal given the low density of Env on the virion’s surface. 
Second, our model assumed that the % neutralization of HIV-1 decreases linearly with the 
number of unbound Env trimers (Appendix A); such a linear relationship has been observed 
when less than half the HIV-1 spikes are bound (56), although it may not hold when more than 
half of the spikes are bound (possibly because some minimum number of unbound Env trimers 
are needed to successfully infect a cell). In a similar vein, we neglected the variability in the 
numbers of spikes per virion (23-26), instead assuming that all virions had exactly 14 spikes. 
However, relaxing these assumptions yielded nearly identical results (Appendix A), suggesting 
that the model is robust to these assumptions. 
 
A compelling extension of this work that would deepen our understanding of the antibody 
response against HIV-1 would be to consider reagents with more than two Fabs. As has been 
seen in other biological systems (67-69), synthetic antibodies with greater valency can elicit 
tighter binding. Hence, a triFab that allows three Fabs to simultaneously bind to an HIV-1 Env 
trimer is predicted to have a lower IC50 than an optimal diFab; indeed, our model predicts that 
an optimal triFab would have an IC50 that is 100x more potent than the optimal (d=62, s=12) 
diFab (see Appendix F). Modeling verifies that a rigid linker is required for a bivalent or trivalent 
reagent to achieve avidity effects by intra-spike crosslinking, thus providing guidance for 
constructing optimal anti-HIV-1 therapeutics that remain potent against HIV-1 in the face of the 
Env mutations arising during HIV-1 replication.  
 
Multivalency has been harnessed in an array of fields that extend beyond immunology; e.g., 
novel materials and scaffolds have been designed at the super-cellular scale using multivalency 
(70), and molecular targeting and molecular machines employ multivalency at the molecular 
scale (69, 71, 72). We hope that our work presents a step towards precise, quantitative models 
that encompasses multivalent binding in each of these contexts. 
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Methods 
 
Expression and Purification of Fabs 
The gene encoding the 3BNC60 light chain was modified using site-directed mutagenesis to 
remove the C-terminal cysteine that forms a disulfide bond with the Fab heavy chain, leaving a 
single free cysteine at the C-terminus of the Fab heavy chain as described (21). Modified light 
chain genes and genes encoding 6xHis-tagged 3BNC60 Fab heavy chains (VH–CH1–tag) were 
subcloned separately into the pTT5 mammalian expression vector (NRC Biotechnology 
Research Institute). 3BNC60 Fabs and IgG were expressed by transient transfection in HEK 
293-6E (NRC Biotechnology Research Institute) cells as described (73) and purified from 
supernatants by Ni-NTA affinity chromatography followed by size exclusion chromatography in 
PBS pH 7.4 using a Superdex 200 10/300 or Superdex 200 16/600 column (Amersham 
Biosciences). 
 
DNA Conjugation to Fabs 
ssDNA was synthesized, phosphorylated, and PAGE purified by Integrated DNA 
Technologies and conjugated to modified 3BNC60 Fab using a previously-described protocol 
(21). Briefly, 3BNC60 Fab was reduced in buffer containing 10mM TCEP-HCl pH 7-8 for two 
hours, and then buffer exchanged three times over Zeba desalting columns (Thermo Scientific). 
The percentage of reduced Fab was determined using Measure-IT Thiol Assay (Invitrogen). 
Concurrently, ssDNA containing a 5’ amino group (Integrated DNA Technologies, IDT-DNA) 
was incubated with a 100-200–fold molar excess of Sulfo-SMCC, an amine-to-sulfhydryl 
crosslinker (Thermo Scientific) for 30 minutes to form a maleimide-activated DNA strand, which 
was buffer exchanged as described above and incubated overnight. The Fab-ssDNA conjugate 
was purified by anion exchange chromatography using MonoQ resin (GE Biosciences) to 
separate unreacted Fab and ssDNA from the conjugate.  
 
The NUPACK server (74) was used to predict thermally-stable DNA sequences lacking 
secondary structures to make dsDNA bridges. Bridge and linker sequences are listed in Table 
S4 (Appendix G). For di-Fabs containing dsDNA bridges longer than 40bp, complementary 
ssDNAs were annealed by heating (95°C) and cooling (room temperature) to create dsDNA 
containing overhangs complementary to the Fab-ssDNA conjugates. dsDNA was purified by 
size exclusion chromatography (Superdex 200 10/300) and incubated overnight with the 
corresponding tagged Fab-ssDNA conjugates. DiFab reagents were purified by Ni-NTA affinity 
chromatography to remove free DNA and excess Fab-ssDNA conjugates, treated with T4 DNA 
ligase (New England Biolabs), and purified again by size exclusion chromatography. To make 
di-Fabs containing dsDNA bridge lengths less than 40bp or containing gapped sequences, two 
complementary ssDNA-conjugated Fabs were incubated at 37°C without a dsDNA bridge and 
then purified as described above. Protein-DNA reagents were stable at 4°C for >6 months as 
assessed by SDS-PAGE. 
 
Characterization of DNA-Fab Reagents 
Fractions from the center of an SEC elution peak were concentrated using Amicon Ultra-15 
Centrifugal Filter Units (Millipore) (MW cutoff = 10 kDa) to a volume of 500 μL. DLS 
measurements were performed on a DynaPro NanoStar DLS instrument (Wyatt Technology) 
using the manufacturer’s suggested settings (10 acquisitions/measurement). Autocorrelation 
data were fit using the Dynamics software package with the globular protein MW-R model and 
compared using both cumulant and regularization fits to give a hydrodynamic radius for each 
diFab. Three independent DLS measurements were performed for each sample and the results 
were averaged. 
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In Vitro Neutralization Assays 
The 6535.3 pseudovirus for in vitro neutralization assays was generated by co-transfecting 
HEK293T cells with vectors encoding Env and a replication-deficient HIV-1 backbone (obtained 
from the Fraunhofer Institute IBMT) as described (40). Neutralization was monitored by the 
reduction of HIV-1 Tat-induced luciferase reporter gene expression in the presence of a single 
round of pseudovirus infection in TZM-bl cells using a protocol modified from (40). To avoid 
false positive neutralization signals from dsDNA-containing reagents potentially due to the 
inclusion of DEAE-dextran, which can interact with DNA (75), we eliminated DEAE-dextran from 
the assays in which the dsDNA linker alone reduced infectivity and increased the pseudovirus 
concentration by 2.5–40-fold as described (21). Comparisons of IC50 values for 3BNC60 IgG 
and Fab derived from neutralization assays conducted in the presence and absence of DEAE-
dextran showed no systematic differences (unpublished results). 
 
Some of the neutralization data were derived from neutralization assays prepared by a Freedom 
EVO® (Tecan) liquid handler (IC50 values derived from manual and robotic assays agreed to 
within 2-4 fold; unpublished results). Reagents (3-, 4-, or 5-fold dilution series; each 
concentration in duplicate) were incubated with 250 (when DEAE dextran was added) or >1000 
(when DEAE dextran was not added) viral infectious units at 37°C for one hour prior to 
incubation with reporter cells (10,000/well) for 48 hours. Luciferase levels were measured from 
a cell lysate using an Infinite 200 Pro microplate reader (Tecan) after addition of BrightGlo 
(Promega). For constructs where multiple replicates of the neutralization curves were measured, 
a representative curve whose IC50 was closest to the mean value is shown in Figs. 3-5. 
 
Fitting Neutralization Assays 
Data were first analyzed using HIV Antibody Database (76) and then fit using nonlinear 
regression to the 2-parameter Hill function 
(
[Ab]
IC50
)
𝑛
1 + (
[Ab]
IC50
)
𝑛 [13] 
to derive experimental IC50 values (Table 2). The IC50 values in Table 1 were previously 
reported and determined in as described (21). 
 
The equilibrium dissociation constant 𝐾𝐷
(1)
 characterizing the binding of the first diFab arm to 
HIV-1 Env (which is equivalent to the dissociation constant between a diFab with only one 
functional arm) is equal to the dissociation constant between a Fab and HIV-1 Env. We 
assumed that the Fab’s neutralization potency was proportional to its ability to bind Env. 
Therefore, rather than fitting 𝐾𝐷
(1)
, we set it to equal the IC50 value for the in vitro neutralization 
assay of the monovalent Fab, namely, 𝐾𝐷
(1)
= 74 ± 31 nM (n=13 replicates). The remaining 
parameters (e.g., 𝑙linker, 𝑙flex, 𝜉ssDNA, 𝛼, ?̃?) were determined using nonlinear regression using 
the neutralization curves for all constructs (see Appendix D and the Supporting Information 
Mathematica notebook where the raw data, the fitting, and the figures are reproduced). 
 
Measurements of Separation Distances on Env Trimer Structures 
We used a single-particle cryo-EM structure (66) of a closed Env trimer bound to 3BNC117, a 
3BNC60-related bNAb (37) for estimating the position of position of CH1 residue 233 (to which 
the DNA linker in the 3BNC60 diFabs was attached) when a 3BNC60 diFab is bound to an Env 
trimer. The coordinates for the VH-VL domains of the 3BNC60 Fab (37) were superimposed on 
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the 3BNC117 VH-VL domains, and the coordinates for the CH1-CL domains from the structure of 
b12 IgG (28) were superimposed on the 3BNC117 CH1-CL domains because CH1 residues 217 
– 233 are disordered in the 3BNC60 Fab structure (37). The model for the 3BNC60 Fab-gp120 
portion of the trimeric cryo-EM complex structure was used to measure the distance between 
adjacent Fab CH1 C-termini in the closed conformation of Env and then modeled into three cryo-
EM structures of Envs in different conformations: an open Env bound by the b12 bNAb in which 
the coreceptor binding sites on the V3 loops are not exposed (63), an open CD4-bound Env 
structure with exposed V3 loops (63), and a partially-open CD4-bound Env in which the gp120 
subunits adopted positions mid-way between closed and fully open (64).  
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Construct Schematic 
dsDNA 
(d) 
ssDNA 
(s) 
Experimentally 
Measured 
IC50 (nM)  
Theoretically 
Predicted 
IC50 (nM) 
Fab 
 
--- --- 27 
 
IgG 
 
--- --- 4.0 
 
Rigidity 
Constructs  
(Fig. 1C, 
Fig. 3)   12 bases 10 bp 12 bases 
10 12 35 74 
 
 
 12 bases 20 bp 12 bases 
20 12 22 74 
 
 
 12 bases 30 bp 12 bases 
30 12 24 74 
 
 
40 12 13 74 
 
 
50 12 8.5 69 
 
 
54 12 2.4 13 
 
 
56 12 2.0 3.6 
 
 
58 12 1.2 1.4 
 
 
60 12 0.82 0.8 
 
 
62 12 0.24 0.6 
 
 
64 12 0.5 0.8 
12  bases 40  bp 12 bases 
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66 12 1.3 1.7 
 
 
68 12 5.2 4.9 
 
 
70 12 8.5 18 
 
 
80 12 15 74 
 
 
90 12 37 74 
 
 
100 12 82 74 
 
Table 1: Experimental and theoretically-determined IC50s for diFabs with linkers 
containing s = 12 bases of flanking ssDNA and different lengths of dsDNA. 
Experimentally-determined IC50 values for 3BNC60 Fab, 3BNC60 IgG, and 3BNC60 diFabs as 
reported in (21). diFabs were composed of d bp dsDNA flanked on both sides by s = 12 ssDNA 
bases.  
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Construct Schematic 
dsDNA 
(d) 
ssDNA 
(s) 
Experimentally 
Measured 
IC50 (nM) 
Theoretically 
Predicted 
IC50 (nM) 
Fab 
 
--- --- 74 ± 31 (n=13) 
 
IgG 
 
--- --- 4.3 ± 0.8 (n=14) 
 
3BNC60-
62bp-
3BNC60  
62 12 0.5 ± 0.15 (n=5) 0.6 
Rigidity 
Constructs  
(Fig. 3)  
58 14 2.0 1.3 
 
 
50 18 48 ± 32 (n=2) 43 
 
 
40 23 45 ± 15 (n=2) 74 
 
 
30 28 67 ± 36 (n=2) 74 
 
  33 bases 20 bp 33 bases 
20 33 70 ± 33 (n=2) 74 
Extra Long 
Constructs  
(Fig. 4)  
62 17 0.6 0.8 
 
 
62 42 1.8 1.2 
 
 
50 22 31 28 
 
 
50 62 6.1 4.9 
Gapped 
Constructs  
(Fig. 5)  
5105105105* 12 30 74 
30 bp 28 bases 28 bases 
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5105225105* 12 24 74 
* subscript denotes flanking ssDNA length 
 
Table 2: Experimental and theoretically-determined IC50s for new diFabs. 3BNC60 diFabs 
were composed of d bp dsDNA flanked on both sides by s bases of ssDNA. Gapped diFabs (Fig. 
5) are denoted by the lengths of their dsDNA segments with subscripts representing inserted 
ssDNA bases. Experimentally-determined IC50 values for 3BNC60 Fab, 3BNC60 IgG, and (d=62, 
s=12) diFab are reported as the mean and standard deviation for 3BNC60 Fab (n = 13 
independent experiments), 3BNC60 IgG (14 independent experiments), the optimal (d=62, 
s=12) diFab (5 independent experiments), and four of the new diFabs (2 independent 
experiments), and as one value when a single neutralization experiment was conducted.  
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